Outlook Therapeutics (OTLK) Free Cash Flow (2015 - 2026)
Outlook Therapeutics (OTLK) reported Free Cash Flow of -$7.8 million for Q1 2026, up 52.8% year-over-year from -$5.1 million in Q1 2025, and up 47.6% quarter-over-quarter from -$14.9 million in Q4 2025.
Outlook Therapeutics (OTLK) Free Cash Flow (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Free Cash Flow data on file, last reported at -$7.8 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$7.8 million, up 52.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$47.0 million (up 26.54% YoY), and the FY2025 annual result was -$51.8 million, up 24.66% from the prior year.
- Free Cash Flow improved to -$7.8 million in Q1 2026 per OTLK's latest filing, from -$14.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$7.8 million in Q1 2026 and troughed at -$21.1 million in Q2 2022.
- A 5-year average of -$13.6 million and a median of -$13.0 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow slumped 137.44% in 2024, then jumped 52.8% in 2026.
- A 5-year view of Free Cash Flow shows it stood at -$8.9 million in 2022, then plunged by 46.41% to -$13.0 million in 2023, then climbed by 15.84% to -$11.0 million in 2024, then slumped by 36.21% to -$14.9 million in 2025, then jumped by 47.6% to -$7.8 million in 2026.
- Business Quant data shows OTLK's Free Cash Flow at -$7.8 million in Q1 2026, -$14.9 million in Q4 2025, and -$12.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 63,220.27 |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | -7.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.83 Mn |
| Mar 31, 2026 | -7.83 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Dec 31, 2023 | -13.03 Mn |
| Dec 31, 2023 | -13.03 Mn |